CNTX
Context Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.21
+5.88%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.20
From 52W high−93.89%
Volume832850.00
Market cap$18.87M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$0.20
From 52W high
−93.89%
Volume
832850.00
Market cap
$18.87M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
P/E (TTM)
—
RSI (14)
31.3
MomentumView details →
1D Return
+5.88%
YTD Return
−86.05%
SummaryUpdated Jun 1, 2026
Context Therapeutics Inc. (NASDAQ:CNTX) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Philadelphia, Pennsylvania. The company went public in October 2021 and focuses exclusively on developing innovative cancer treatments specifically for women. Context Therapeutics operates as a pre-revenue biotechnology company, dedicating its resources to advancing two primary drug candidates through clinical trials targeting female hormone-dependent cancers and gynecologic malignancies.
Similar companies
Latest newsMore news →
Context Therapeutics announced that the first patient has been dosed in the Phase 1 clinical trial of CT-202, a Nectin-4 x CD3 T cell engaging bispecific antibody, for solid tumors.56d agoContext Therapeutics released interim Phase 1 data for CTIM-76, a CLDN6 x CD3 T-cell engaging bispecific antibody, in patients with advanced platinum-resistant ovarian cancer.142d ago